Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03783871
Other study ID # NEU_2017_07
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 17, 2019
Est. completion date January 17, 2024

Study information

Verified date March 2024
Source Ethicon, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the informed consent, will be enrolled. The patients will be treated with MW ablation and afterwards followed for up to 36 months after the original ablation procedure to assess efficacy and safety. In addition to the final analysis after all enrolled patients complete the 36-month observation period, a summary of selected endpoints will be provided after all enrolled patients have completed each of the 1-month and 12-month visits. To provide sites with an opportunity to get equal experience in the use of the Certus system, there will 3 patients treated as part of a run-in phase. These patients will only be included in the safety set.


Description:

Patients who have a single HCC tumor up to 5 cm or a maximum of 3 HCC tumors of up to 3 cm per tumor will receive the same procedure: microwave ablation using only the NeuWave Certus Microwave Ablation System. Patients in this study will come to their study site for the ablation procedure. After the ablation procedure, the patient will be observed, which in most cases is expected to be 2 to 3 hours, and afterwards may return home. If the Study Doctor decides it is warranted for patient safety, the patient will remain in the hospital longer. A minimum of one MRI of the liver must be taken at Baseline/Screening to ascertain tumor type, location, and size. (Tumor size will be measured in longest diameter and the diameter that is perpendicular to this longest diameter; tumor size must be measured with at least 2D imaging.) Physicians who are experienced with tumor ablation will do all ablations percutaneously using only the NeuWave Certus Ablation System. During the ablation, patients will be under an anesthesia method as per the institution's SOC. Ultrasound and/or CT scan will be used to guide the probe to the tumor and confirm accurate placement of the probe prior to emitting the microwaves. Within 7 days after ablation, contrast-enhanced MRI will be done to confirm the completion of the ablation procedure. According to the standard practice at each study site, ablation confirmation will be classified as: - complete tumor ablation with adequate margin (A0). - complete tumor ablation with insufficient margin (A1). - incomplete tumor ablation (A2). Over the course of 3 years, patients will return to their study site for post ablation follow-up visits, which will be carried out per the Schedule of Activities (see Table 1 at the end of the Synopsis). The follow-up schedule will be based on the original ablation procedure date. A re-ablation for any reason will not re-start or change the follow-up visit schedule. At every follow-up visit, every patient will be scanned with at least one MRI to see if there are any tumor foci at the edge of the ablation zone, which indicates tumor progression. Repeat microwave ablation (using the Certus Microwave Ablation System only) may be performed for recurrence of target tumor(s) or to achieve complete tumor ablation with adequate margin (A0) of the target tumor(s) if the initial ablation had an insufficient margin, if the treating physician deems appropriate and necessary. While repeat ablations for a recurrence may be conducted at any point during the study duration, repeat ablations to correct an ablative margin may only be performed within the first 30 days of the original ablation (by Visit 3).


Recruitment information / eligibility

Status Completed
Enrollment 135
Est. completion date January 17, 2024
Est. primary completion date January 17, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed primary or recurrent HCC determined in accordance with the institution's SOC procedure, a single tumor size up to 5 cm or a maximum of 3 tumors up to 3 cm per tumor. Tumor size must be measured with at least 2-dimensional (2D) imaging. - Scheduled for microwave ablation of the liver. - Performance status 0-2 (Eastern Cooperative Oncology Group classification). - Functional hepatic reserve based on the Child-Pugh score (Class A or B). - Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule. - At least 18 years of age. Exclusion Criteria: 1. ASA score = 4. 2. Active bacterial or fungal infections which are clinically significantly. 3. Chemotherapy or radiation therapy for HCC performed within 30 days prior to the study procedure. 4. Patient with implantable pacemakers or other electronic implants. 5. Planned/ scheduled liver surgery. 6. Platelet count = 50 × 109/L. 7. Patients with uncorrectable coagulopathy at time of screening based on investigator judgement. Severe blood coagulation dysfunction (bleeding tendency, prothrombin time [PT] was greater than normal control for 3~5 seconds, platelet count [PLT] was less than 50x109/L, and the international normalized ratio [INR] was greater than 1.5). 8. Patient with renal failure and on renal dialysis. 9. Scheduled concurrent procedure other than MW ablation in the liver. 10. Pregnant or breast feeding. 11. Physical or psychological condition which would impair study participation. 12. Participation in any other interventional clinical study within 1 month before screening and concurrently during the study. 13. The patient is judged unsuitable for study participation by the investigator for any other reason.

Study Design


Intervention

Device:
Microwave ablation
Subjects will be treated with microwave ablation.

Locations

Country Name City State
China Chinese PLA General Hospital Beijing
China Sun Yat-sen University Cancer Center Guangzhou Guangdong
China The First Affiliated Hospital,Sun Yat-sen University Guangzhou Guangdong
China Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ethicon, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety Endpoint Adverse events (AEs) and serious adverse events (SAEs) reported at each analysis and cumulatively throughout the entire study period. 1,3,6,9,12,18,24,30,36 months
Other Numeric Pain Rating Scale The Numeric Pain Rating Scale (NPRS) is a patient-reported outcome. Patients will complete this scale before the ablation procedure (measured at the Screening Visit), post ablation (within 7 days after ablation), and at the 1-month follow-up visit.
This scale ranges from 0 (no pain) to 10 (worst possible pain).
7 days/1 month(±7days)
Other EORTC QLQ-C30 Questionnaire EORTC QLQ-C30 is a patient-reported questionnaire that assesses the health-related quality-of-life (QOL) of cancer patients. This questionnaire is assessed before the ablation procedure (measured at Screening Visit), post ablation (within 7 days after ablation), and at each follow-up visit.
The questionnaire individual questions range in scores from 0 to 100 with a higher score correlating to a better quality of life for the patient for 'function' questions but correlates to worse symptoms for 'symptom' questions.
7days/1,3,6,9,12,18,24,30,36 months
Other EORTC QLQ-HCC18 Questionnaire EORTC QLQ-HCC18 is a patient-reported questionnaire that assesses the health-related quality-of-life (QOL) of hepatocellular cancer patients. This questionnaire is assessed before the ablation procedure (measured at Screening Visit), post ablation (within 7 days after ablation), and at each follow-up visit.
All individual questions are scored from 0 to 100 with a higher score correlating with a more severe symptom or problem.
7days/1,3,6,9,12,18,24,30,36 months
Primary Primary Technical Efficacy defined as a combination of A0 ablations (complete tumor ablation with a surrounding 5 mm margin) and A1 ablations (complete tumor ablation with inadequate margins), based on contrast-enhanced MRI scans at 1 month (+/- 7 days) after the original ablation procedure. 1 month (+/- 7 days)
Secondary Technical Success defined as a combination of A0 ablations (complete tumor ablation with a surrounding 5 mm margin) and A1 ablations (complete tumor ablation with inadequate margins) based on contrast-enhanced Magnetic Resonance Imaging (MRI) performed up to 7 days following the original ablation procedure. 7 days
Secondary Progression-Free Survival defined as length of time from the original ablation procedure until any type of disease progression (i.e. local or distant). 1,3,6,9,12,18,24,30,36 months
Secondary Secondary efficacy rate defined as the percentage of tumors that have undergone successful repeat ablation following identification of local tumor progression at any time during study follow up. 1,3,6,9,12,18,24,30,36 months
Secondary Overall-survival, measured from the time of the original ablation procedure to the time of death or last follow-up, if death has not occurred. 1,3,6,9,12,18,24,30,36 months
Secondary Local tumor progression (LTP) evaluated at every visit after the ablation of the target tumor. LTP describes the appearance of tumor foci at the edge of the ablation zone, after at least one contrast-enhanced follow-up MRI scan has documented adequate ablation and an absence of viable tissue in the target tumor and surrounding ablation margin by using imaging criteria. 1,3,6,9,12,18,24,30,36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2